LKT Laboratories, Inc.

Pramipexole Dihydrochloride

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID P6901
CAS No. 191217-81-9
Chemical Name (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride
Synonym



Formula $C_{10}H_{17}N_3S \cdot 2HCl \cdot H_2O$
Formula Wt. 302.26
Melting Point 288-290°C
Purity ≥98%
Solubility

Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
P6901	10 mg	$74.90
P6901	25 mg	$119.90
P6901	100 mg	$314.70

Store Temp Ambient
Ship Temp Ambient
Description Pramipexole is an agonist at D2/3 receptors that is clinically used to treat symptoms of Parkinson's disease. Pramipexole exhibits neuroprotective and antidepressant activities. In animal models, pramipexole decreases immobility time in the forced swim test. In vitro, this compound inhibits LPS-induced degeneration of neurons and also inhibits phosphorylation of α-synuclein.

References

Chau KY, Cooper JM, Schapira AH. Pramipexole reduces phosphorylation of α-synuclein at serine-129. J Mol Neurosci. 2013 Oct;51(2):573-80. PMID: 23681749.

Kitagawa K, Kitamura Y, Miyazaki T, et al. Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jul;380(1):59-66. PMID: 19274453.

Iravani MM, Sadeghian M, Leung CC, et al. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol. 2008 Aug;212(2):522-31. PMID: 18571649.

Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004 Jul 1;56(1):54-60. PMID: 15219473.

Ling ZD, Robie HC, Tong CW, et al. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharmacol Exp Ther. 1999 Apr;289(1):202-10. PMID: 10087005.

Ono K, Takasaki J, Takahashi R, et al. Effects of antiparkinsonian agents on beta-amyloid and alpha-synuclein oligomer formation in vitro. J Neurosci Res. 2013 Oct;91(10):1371-1381. PMID: 23913715.